Claims for Patent: 8,802,717

Summary for Patent: 8,802,717

Title:	Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline 1,3-dione
Abstract:	Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoin- doline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-.alpha. or the inhibition of PDE4.
Inventor(s):	Muller; George W. (Rancho Santa Fe, CA), Schafer; Peter H. (Somerset, NJ), Man; Hon-Wah (Princeton, NJ), Ge; Chuansheng (Belle Mead, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	13/682,652
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,802,717
Patent Claims:	1. A method of treating an arthritic condition, which comprises administering to a patient having an arthritic condition a therapeutically effective amount of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetyla- minoisoindoline-1,3-dione. 2. The method of claim 1, wherein the arthritic condition is rheumatoid spondylitis. 3. The method of claim 1, wherein the compound is administered orally. 4. The method of claim 3, wherein about 5 mg to about 500 mg of the compound is administered per day. 5. The method of claim 3, wherein about 10 mg to about 200 mg of the compound is administered per day. 6. The method of claim 3, wherein about 10 mg to about 100 mg of the compound is administered per day. 7. The method of claim 3, wherein the compound is administered twice daily in equally divided doses. 8. The method of claim 3, wherein the stereomerically pure compound comprises greater than about 90% by weight of (+) isomer based on the total weight percent of the compound. 9. The method of claim 3, wherein the stereomerically pure compound comprises greater than about 95% by weight of (+) isomer based on the total weight percent of the compound. 10. The method of claim 3, wherein the stereomerically pure compound comprises greater than about 97% by weight of (+) isomer based on the total weight percent of the compound. 11. The method of claim 3, wherein the compound is administered in capsule form. 12. The method of claim 1, wherein the capsule contains about 10 mg of the compound. 13. The method of claim 11, wherein the capsule contains about 20 mg of the compound. 14. The method of claim 11, wherein the capsule contains about 25 mg of the compound. 15. The method of claim 11, wherein the capsule contains about 50 mg of the compound. 16. The method of claim 1, wherein the compound is administered in tablet form. 17. The method of claim 16, wherein the tablet contains about 10 mg of the compound. 18. The method of claim 16, wherein the tablet contains about 20 mg of the compound. 19. The method of claim 16, wherein the tablet contains about 25 mg of the compound. 20. The method of claim 16, wherein the tablet contains about 50 mg of the compound. 21. A method of treating an arthritic condition, which comprises orally administering to a patient having an arthritic condition about 10 mg to about 100 mg of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione comprising greater than about 97% by weight of (+) isomer wherein the compound is administered in the form of a tablet or capsule twice daily in equally divided doses. 22. The method of claim 21, wherein the arthritic condition is rheumatoid spondylitis.